Latest News on QGEN

Financial News Based On Company


Advertisement
Advertisement

Qiagen stock: Shareholders approve Pratt as CEO

https://www.ad-hoc-news.de/boerse/news/corporate-news/qiagen-stock-shareholders-approve-pratt-as-ceo/70521908
Qiagen shareholders have approved Jonathan M. Pratt as the new CEO and managing director at an extraordinary general meeting held on November 6, 2026. This leadership change occurs as Qiagen's all-cash takeover by EQT remains pending, with the company having suspended its 2026 outlook. Pratt's formal appointment follows his joining the company on September 1, adding a new focal point for investors amid the ongoing acquisition process.

Weekly Recap: BlackRock stake rises and UBS keeps Neutral, raises target

https://www.tradingview.com/news/tradingview:638f6b2ca2b9b:0-weekly-recap-blackrock-stake-rises-and-ubs-keeps-neutral-raises-target/
BlackRock increased its reported stake in QIAGEN NV (QGEN), holding 12.73% of share capital and 14.05% of voting rights as of November 5, 2026. Concurrently, UBS maintained its Neutral rating on QIAGEN NV and raised its price target for the stock from $48 to $50.

Qiagen (QGEN) Shareholders Approve Jonathan M Pratt As CEO And Managing Director

https://sg.finance.yahoo.com/news/qiagen-qgen-shareholders-approve-jonathan-121736760.html
Qiagen (NYSE:QGEN) shareholders have approved Jonathan M. Pratt as the new CEO and Managing Director, succeeding Thierry Bernard. This leadership change comes as Qiagen recently reported Q3 2026 sales of US$547.87 million, with investors now focusing on how Pratt will execute the company's strategy, particularly in automation, QuantiFERON, and digital PCR. The market will be watching upcoming quarterly reports and guidance for evidence of consistent execution under the new leadership.

QIAGEN N.V. (QIA) T. Rowe Price Reports 2.97% of Voting Rights

https://www.tradingview.com/news/tradingview:a0adab4be5c53:0-qiagen-n-v-qia-t-rowe-price-reports-2-97-of-voting-rights/
The AFM has disclosed that T. Rowe Price Group reported holding 2.98% of QIAGEN's capital interest and 2.97% of voting rights as of November 5, 2026. This notification is an ownership disclosure, not an operating update, and provides no prior-period comparison to indicate a change in T. Rowe Price's position. Further filings or company announcements related to this investor would be needed to establish a trend or significant catalyst.

QIAGEN N.V. (QIA) Reports Bank of America Voting Rights Notification

https://www.tradingview.com/news/tradingview:7f198c08e5bf8:0-qiagen-n-v-qia-reports-bank-of-america-voting-rights-notification/
QIAGEN N.V. (QIA) received a notification from the AFM on November 10, 2026, regarding Bank of America Corporation's voting rights. The transaction date was November 5, 2026, but the release did not specify a share count or percentage. An AI analyst notes that while this indicates an ownership change, the lack of stake size or direction means its impact as a catalyst is unclear without further details from the AFM.
Advertisement

Weekly Recap: 2026 guidance suspended and Q3 revenue beats outlook

https://www.tradingview.com/news/tradingview:d08d86b868100:0-weekly-recap-2026-guidance-suspended-and-q3-revenue-beats-outlook/
QIAGEN NV (QGEN) suspended its 2026 financial guidance due to EQT Private Equity's pending offer of €46.50 per share. The company reported a 2.8% increase in Q3 2026 revenue to $548 million, surpassing its outlook, with adjusted diluted EPS rising to $0.65. Additionally, CEO Jonathan M. Pratt's appointment to the Managing Board was approved, and BlackRock's stake in the company increased to 12.13%.

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

https://www.biospace.com/press-releases/qiagen-shareholders-overwhelmingly-approve-jonathan-m-pratt-as-managing-director
QIAGEN N.V. announced that its shareholders have overwhelmingly approved Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board. Pratt joined QIAGEN as Chief Executive Officer on September 1, 2026, and now joins Roland Sackers, CFO, on the Managing Board. Shareholders also approved the discharge of Thierry Bernard for his service as a Managing Board member until he stepped down on September 1, 2026.

QIAGEN Selects Medrio EDC for In Vitro Diagnostic Studies

https://www.clinicaltrialvanguard.com/news/qiagen-selects-medrio-edc-for-in-vitro-diagnostic-studies/
QIAGEN has chosen Medrio EDC for its in vitro diagnostic (IVD) studies, driven by the need for predictable costs and internal control over study builds. Traditional EDC platforms designed for drug trials often don't suit the data generation methods of lab environments, leading to higher costs and delays. Medrio's platform offers the necessary flexibility for form design, regulatory compliance (21 CFR Part 11), and self-sufficiency for QIAGEN's data management staff, addressing key challenges in IVD clinical investigations.

QIAGEN N.V. (QIA) JPMorgan Reports 5.05% Holding

https://www.tradingview.com/news/tradingview:09e5d376bf81a:0-qiagen-n-v-qia-jpmorgan-reports-5-05-holding/
JPMorgan Chase & Co. reported a 5.05% holding in QIAGEN's capital interest and voting rights as of October 30, 2026, with 1.81% indirect real and 3.24% indirect potential. This disclosure indicates a notable ownership threshold but is not a reported change in QIAGEN's operations or financial results. A future filing showing a material change would be a larger catalyst.

QIAGEN N.V. (QIA) Reports MFS Holding 3.44% of Voting Rights

https://www.tradingview.com/news/tradingview:1bf2dc7e885a7:0-qiagen-n-v-qia-reports-mfs-holding-3-44-of-voting-rights/
Massachusetts Financial Services Company (MFS) has disclosed to the AFM that it holds 3.44% of QIAGEN N.V.'s voting rights and 2.82% of its capital interest, with the transaction occurring on October 29, 2026. This is an ownership disclosure and does not reflect a change in QIAGEN's operating outlook or financial results. A further disclosure from the AFM or a company announcement would be needed for a larger catalyst.
Advertisement

Qiagen net income for three months ended Sept. 30, 2026 falls 19% to USD 105.66 million

https://www.vermoegenszentrum.ch/en/stock-exchange-and-markets/news/qiagen-net-income-three-months-ended-sept-30-2026-falls-19-usd
Qiagen's net income for the three months ending September 30, 2026, decreased by 19% year-over-year, reaching USD 105.66 million, despite a rise in net sales. The company also experienced more than double restructuring and acquisition expenses. This financial update follows an all-cash takeover offer for Qiagen at EUR 46.50 per share, valuing the business at approximately EUR 10.8 billion.

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

https://www.tradingview.com/news/reuters.com,2026-11-06:newsml_PexdRs1Za:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/
QIAGEN N.V. has released a voting rights announcement as required by Article 40, Section 1 of the WpHG, following a notification from the AFM. The announcement details BlackRock, Inc.'s substantial holdings in QIAGEN N.V., including both ordinary shares and contracts for difference, with a total capital interest of 11.87% and voting rights of 13.18%. The transaction date was November 2, 2026, and the information is available on the AFM website.

QIAGEN N.V. (QIA) Reports Voting Rights Disclosure by Massachusetts Financial Services

https://www.tradingview.com/news/tradingview:cb5e28743f9b6:0-qiagen-n-v-qia-reports-voting-rights-disclosure-by-massachusetts-financial-services/
QIAGEN N.V. (QIA) announced a voting rights disclosure by Massachusetts Financial Services Company, as informed by the AFM on November 3, 2026. The transaction date was October 29, 2026, but the release did not specify the stake size or whether it was a buy or sale. An AI analyst noted that without these details, it's unclear if the ownership change is a significant catalyst.

QIAGEN N.V. (QIA) Reports Bank of America Voting Rights Notification

https://www.tradingview.com/news/tradingview:006f08276ca42:0-qiagen-n-v-qia-reports-bank-of-america-voting-rights-notification/
QIAGEN N.V. announced that the AFM informed it of a voting rights notification from Bank of America Corporation, with a transaction date of November 2, 2026. The notification did not specify the holding size or percentage of voting rights. An AI Analyst noted that while it's an ownership disclosure, the release lacks details on the stake size or whether it increased or decreased, requiring further AFM register details.

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

https://www.quantisnow.com/insight/qiagen-shareholders-overwhelmingly-approve-jonathan-m-pratt-as-managing-director-6778330
QIAGEN shareholders have officially approved Jonathan M. Pratt as a Managing Director and member of the Managing Board. Pratt previously joined the company as Chief Executive Officer on September 1, 2026. This approval formalizes his position alongside CFO Roland Sackers, while shareholders also approved the discharge of former CEO Thierry Bernard, who stepped down on the same date.
Advertisement

QIAGEN Shareholders Overwhelmingly Approve Jonathan M. Pratt as Managing Director

https://www.businesswire.com/news/home/20261106227567/en/QIAGEN-Shareholders-Overwhelmingly-Approve-Jonathan-M.-Pratt-as-Managing-Director
QIAGEN N.V. announced that its shareholders overwhelmingly approved the appointment of Jonathan M. Pratt as a Managing Director and member of the QIAGEN Managing Board. Mr. Pratt joined QIAGEN as CEO on September 1, 2026, and now joins Roland Sackers on the Managing Board. Shareholders also approved the discharge of former CEO Thierry Bernard for his service.

Qiagen shareholders approve Jonathan Pratt as managing director

https://www.investing.com/news/company-news/qiagen-shareholders-approve-jonathan-pratt-as-managing-director-93CH-5008719
QIAGEN N.V. shareholders have approved the appointment of Jonathan M. Pratt as a Managing Director and member of the Managing Board. Pratt, who became CEO on September 1, 2026, now joins Roland Sackers on the Managing Board. The shareholders also discharged Thierry Bernard from his service following his departure as CEO and Managing Board member on the same date.

Three Wellington entities each report the same-sized QIAGEN (QGEN) stake in an ownership amendment.

https://www.stocktitan.net/sec-filings/QGEN/schedule-13g-a-qiagen-n-v-amended-passive-investment-disclosure-6e70d0d871ec.html
Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP have each reported a beneficial ownership of 1,869,523 common shares in QIAGEN N.V. (QGEN), representing 0.91% of the class. This amended passive investment disclosure, filed as a SCHEDULE 13G/A, indicates that the shares are owned by clients of Wellington investment advisers, with the reporting entities holding shared voting and dispositive authority.

PTA-CMS: QIAGEN N.V.: Release of a capital market information

https://www.tradingview.com/news/reuters.com,2026-11-06:newsml_Pex9Jp6Ha:0-pta-cms-qiagen-n-v-release-of-a-capital-market-information/
QIAGEN N.V. announced the filing of its Form 6-K Report for the quarterly period ended September 30, 2026, with the United States Securities and Exchange Commission (SEC). The document is now accessible on QIAGEN's official website. This release provides updated capital market information to investors.

Qiagen stock: Q3 margin rises as EQT deal suspends outlook

https://www.ad-hoc-news.de/boerse/news/corporate-news/qiagen-stock-q3-margin-rises-as-eqt-deal-suspends-outlook/70465340
Qiagen announced its final third-quarter results, with sales increasing 3% to $548 million and adjusted operating margin rising to 30.4%, surpassing its own outlook. However, the company has suspended its 2026 outlook due to the pending all-cash acquisition by EQT Private Equity, which offers 46.50 euros per share, making the transaction timetable the primary focus for shareholders.
Advertisement

QIAGEN Reports Full Q3 2026 Results

https://www.biospace.com/press-releases/qiagen-reports-full-q3-2026-results
QIAGEN N.V. announced its full results for the third quarter of 2026, reporting net sales of $548 million, a 3% increase over Q3 2025, and adjusted diluted EPS of $0.65, exceeding their outlook. Due to a pending transaction with EQT Private Equity, the company has suspended its 2026 financial guidance. The results highlight growth in consumables and robust adjusted operating income margins.

Third-quarter sales rose 3%, but QIAGEN suspended its 2026 outlook while a deal is pending.

https://www.stocktitan.net/news/QGEN/qiagen-reports-full-q3-2026-275mm2i4u54y.html
QIAGEN N.V. (NYSE: QGEN) announced its full third-quarter 2026 results, with net sales increasing 3% to $548 million and adjusted diluted EPS rising to $0.65, both exceeding expectations. Due to a pending transaction with EQT Private Equity, the company has suspended its 2026 financial outlook. Consumables and related revenues accounted for 91% of sales and grew 3% at constant exchange rates.

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

https://www.tradingview.com/news/reuters.com,2026-11-02:newsml_Pex647csa:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/
QIAGEN N.V. has released a voting rights announcement, disclosing that the AFM (the Netherlands Authority For the Financial Markets) informed them of a notification from BlackRock, Inc. The notification details BlackRock's holdings in QIAGEN N.V. as of October 28, 2026, showing both real and potential capital interest and voting rights across various BlackRock entities. The total capital interest is reported at 11.52% and total voting rights at 12.85%.

Release according to Article 40, Section 1 of the WpHG

https://www.tradingview.com/news/reuters.com,2026-11-03:newsml_PexMYxpKa:0-release-according-to-article-40-section-1-of-the-wphg/
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, based on a notification from the AFM. The announcement details changes in voting rights related to transactions on October 28, 2026, where Barclays Plc disclosed various holdings in QIAGEN N.V. shares, convertible bonds, and swaps, totaling a capital interest and voting rights of 6.41%.

QIAGEN N.V. (QIA) Manager Released 15,349 Performance Stock Units

https://www.tradingview.com/news/tradingview:2c050a34195a4:0-qiagen-n-v-qia-manager-receives-8-075-shares-in-net-settlement/
QIAGEN N.V. manager Roland Sackers received 8,075 common shares through a net settlement after 15,349 performance stock units were released, and 22,895 previously pledged shares were returned. This transaction is an insider disclosure related to a prior share-based compensation grant, not a new operating or financial update. The release does not specify transaction prices or volumes.
Advertisement

QIAGEN N.V. (QIA) Reports Barclays' 6.41% Voting Rights Position

https://www.tradingview.com/news/tradingview:046ae2ffd3e91:0-qiagen-n-v-qia-reports-barclays-6-41-voting-rights-position/
The AFM has disclosed that Barclays Plc reported a 6.41% capital interest and voting rights position in QIAGEN N.V. This holding includes 0.33% held indirectly as real voting rights and 6.07% as potential voting rights, indicating that the majority of the reported exposure is potential rather than current. This disclosure reflects an ownership position rather than a change in QIAGEN's operational performance.

QIAGEN N.V. (QIA) JPMorgan Reports 4.73% Stake

https://www.tradingview.com/news/tradingview:8217645639429:0-qiagen-n-v-qia-reports-jpmorgan-s-4-73-holding/
JPMorgan Chase & Co. has disclosed a 4.73% holding in QIAGEN N.V. (QIA), consisting of 1.59% indirect real and 3.14% indirect potential interests, with the transaction date being October 27, 2026. This disclosure is an ownership update and does not reflect changes in QIAGEN's operational performance. The majority of JPMorgan's reported position is potential rather than real, indicating it does not represent equivalent current voting ownership.

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

https://www.tradingview.com/news/reuters.com,2026-11-03:newsml_PexHwsQJa:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/
QIAGEN N.V. has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM. The notification, disclosed on October 31, 2026, details transactions from October 28, 2026, involving Barclays Plc and its subsidiaries, outlining various types of shares, convertible bonds, and swaps with their respective voting rights and capital interests. The total indirect real and potential capital interest and voting rights held by Barclays Plc in QIAGEN N.V. is stated as 6.41%.

QIAGEN N.V. (QIA) Reports Managers' Transactions

https://www.tradingview.com/news/tradingview:0b0ca8e5d4eb3:0-qiagen-n-v-qia-reports-managers-transactions/
QIAGEN N.V. (QIA) has issued a managers' transactions announcement under Article 19 MAR, but the release does not provide specific transaction details such as names, sizes, or direction. An AI analyst notes that while insider transactions can influence sentiment, the lack of these crucial details makes it difficult to assess the potential market impact of this disclosure. Further information is required to understand its significance.

PTA-DD: QIAGEN N.V.: Managers' transactions announcement according to article 19 MAR

https://www.tradingview.com/news/reuters.com,2026-11-03:newsml_PexTMVZFa:0-pta-dd-qiagen-n-v-managers-transactions-announcement-according-to-article-19-mar/
QIAGEN N.V. announced details of a manager's transaction involving Roland Sackers, a member of the managing body. The transaction involved the release of 15,349 Performance Stock Units, the receipt of 8,075 Common Shares upon net share settlement, and the return of 22,895 previously pledged shares. These actions are linked to the exercise of share option programs and occurred on October 31, 2026.
Advertisement

QIAGEN N.V. (QIA) Reports BlackRock Holding 12.85% of Voting Rights

https://www.tradingview.com/news/tradingview:a3ca94cebe688:0-qiagen-n-v-qia-reports-blackrock-holding-12-85-of-voting-rights/
An AFM disclosure from October 30 reveals that BlackRock holds 12.85% of QIAGEN N.V. (QIA) voting rights, comprising 9.69% indirectly real and 3.16% indirectly potential. The capital interest was reported at 11.52%. This disclosure indicates BlackRock as a significant voting-rights holder, though it is not indicative of a new strategic change or a shift in BlackRock's position.

Qiagen N.V. (QGEN) stock price, news, quote and history

https://sg.finance.yahoo.com/quote/QGEN/
This Yahoo Finance page provides a comprehensive overview of Qiagen N.V. (QGEN) stock, including its real-time price, overnight trading activity, and a range of key financial statistics. It offers interactive charts, historical data, and sections for news, analysis, and financial highlights. The page also lists related stocks that people frequently watch.

QIAGEN N.V. (QIA) Reports T. Rowe Price Holds 5.34% of Voting Rights

https://www.tradingview.com/news/tradingview:a3af834411103:0-qiagen-n-v-qia-reports-t-rowe-price-holds-5-34-of-voting-rights/
QIAGEN N.V. announced that T. Rowe Price has reported a holding of 5.34% of voting rights and 5.35% of capital interest, including potential holdings. The disclosure did not include a prior-period comparison. This is an ownership disclosure and does not reflect a change in QIAGEN's operational or financial outlook.

QIAGEN N.V. (QIA) Reports Barclays' 8.77% Holding

https://www.tradingview.com/news/tradingview:d495696fbf288:0-qiagen-n-v-qia-reports-barclays-8-77-holding/
Barclays has reported an 8.77% capital interest and voting rights in QIAGEN N.V. (QIA), consisting of 4.45% indirect real and 4.33% indirect potential holdings. The transaction date for this disclosure was October 27, 2026. An AI analyst notes that this is an ownership disclosure, and the impact depends on whether this is a new position or part of a trend, suggesting a subsequent filing could provide more clarity.

QIAGEN N.V. (QGEN) stock price, news, quote and history

https://uk.finance.yahoo.com/quote/QGEN/
This article provides a detailed overview of QIAGEN N.V. (QGEN) stock, including its current price, historical performance, and key financial metrics. It also includes company information, recent news, analyst ratings, and earnings trends. QIAGEN specializes in sample to insight solutions for molecular diagnostics and life sciences.
Advertisement

Qiagen NV | SC14D9C: Written communication by the subject company relating to a third party tender offer

https://www.moomoo.com/news/notice/1002005242/written-communication-by-the-subject-company-relating-to-a-third
This document is an SC14D9C filing by Qiagen NV, representing written communication from the subject company regarding a third-party tender offer. Further details about the tender offer itself are not provided in this excerpt.

Do Options Traders Know Something About Qiagen Stock We Don't?

https://www.tradingview.com/news/zacks:539fd9936094b:0-do-options-traders-know-something-about-qiagen-stock-we-don-t/
Investors should closely watch Qiagen N.V. (QGEN) due to unusual activity in its options market, particularly the Dec. 18, 2026 $55 Put, which shows high implied volatility. This suggests the market expects a significant price movement, possibly driven by an upcoming event. Analysts currently rate Qiagen as a Zacks Rank #2 (Buy), with recent upward revisions in earnings estimates, hinting at a potential trading opportunity for those looking to sell premium.

QIAGEN N.V. (QIA) Discloses AFM Notice on 2.6% Holding

https://www.tradingview.com/news/tradingview:6fbb053783475:0-qiagen-n-v-qia-discloses-afm-notice-on-2-6-holding/
QIAGEN N.V. (QIA) announced that the Dutch AFM disclosed Millennium International Management LP's 2.60% holding as of October 23, 2026. This holding is primarily composed of potential voting rights from swaps and options, with a smaller portion from ordinary shares. An AI analyst notes that derivatives-driven exposure suggests tactical positioning rather than long-term ownership, and a larger stake change or activism signals would increase the significance of this disclosure.

QIAGEN N.V. (QIA): UBS Notifies 5.82% Voting Rights

https://www.tradingview.com/news/tradingview:dd8b6401ebcef:0-qiagen-n-v-qia-ubs-notifies-5-82-voting-rights/
UBS Group AG has reported a 5.82% holding in QIAGEN N.V. (QIA) as of October 26, 2026, according to a disclosure by the Dutch AFM. This stake comprises 3.27% indirect real voting rights and 2.55% indirect potential voting rights through shares and derivatives. This ownership update indicates a sizable stake that could impact QIAGEN's governance and liquidity.

QIAGEN N.V. (QIA) Barclays Notifies 5.02% Position

https://www.tradingview.com/news/tradingview:80e2a77efebdf:0-qiagen-n-v-qia-barclays-notifies-5-02-position/
Barclays Plc has notified an AFM filing indicating a 5.02% holding in QIAGEN N.V. (QIA) as of October 22, 2026. This position includes both real and potential interests through various financial instruments like shares, CFDs, swaps, and a convertible bond, with the majority being derivative-based. This disclosure marks a regulatory threshold crossing for Barclays, signaling a notable institutional position in QIAGEN.
Advertisement

QIAGEN N.V. (QIA): MFS Notifies 3.85% Capital, 4.59% Votes

https://www.tradingview.com/news/tradingview:cc96e9d67b1c3:0-qiagen-n-v-qia-mfs-notifies-3-85-capital-4-59-votes/
QIAGEN N.V. announced that the Dutch AFM has disclosed that Massachusetts Financial Services Company (MFS) holds a 3.85% capital interest and 4.59% voting rights in the company as of October 23, 2026. This is categorized as a routine substantial holding disclosure, indicating institutional interest rather than a strategic shift.

QIAGEN N.V. (QIA): Barclays Notified at 9.16% Voting Rights

https://www.tradingview.com/news/tradingview:dad94a349b30f:0-qiagen-n-v-qia-barclays-notified-at-9-16-voting-rights/
QIAGEN N.V. (QIA) announced that the Dutch AFM was notified that Barclays plc holds 9.16% of voting rights in QIAGEN as of October 23, 2026. This stake comprises 1.09% indirect real holdings and 8.07% indirect potential holdings through shares and derivatives. This regulatory disclosure highlights a significant position by Barclays, primarily via potential instruments like swaps and CFDs, which could impact future trading flows and governance.

QIAGEN N.V. (QIA) Receives AFM Notice on UBS Voting Rights

https://www.tradingview.com/news/tradingview:eb5a1a45d3939:0-qiagen-n-v-qia-receives-afm-notice-on-ubs-voting-rights/
QIAGEN N.V. (QIA) announced it received a voting rights notification from the Dutch Authority for the Financial Markets (AFM) regarding UBS Group AG, dated October 26, 2026. This notice signals a potential change in a major holder’s position, which could influence the company's stock float and market sentiment. The company notes that the information is based on the AFM register and disclaims responsibility for its accuracy.

QIAGEN N.V. (QIA): JP Morgan Reports 3.20% Voting Rights

https://www.tradingview.com/news/tradingview:b5ea5a3af3f8f:0-qiagen-n-v-qia-jp-morgan-reports-3-20-voting-rights/
JP Morgan Chase & Co. has reported a 3.20% holding in QIAGEN N.V. (QIA) as of October 23, 2026, comprising both real and potential voting rights and capital interest. This mid-cycle ownership update indicates JP Morgan's aggregated exposure through indirect real holdings (1.32%) and indirect potential holdings (1.87%), including instruments like equity swaps and convertible bonds. The report suggests this is a positioning shift, but a larger threshold crossing or activist intent would be needed for a significant market catalyst.

QIAGEN N.V. (QIA): JP Morgan Notified at 3.2% Stake

https://www.tradingview.com/news/tradingview:b5ea5a3af3f8f:0-qiagen-n-v-qia-jp-morgan-notified-at-3-2-stake/
JP Morgan Chase & Co. has reported a 3.20% holding in QIAGEN N.V. (QIA) as of October 23, 2026, comprising both real and potential positions. This mid-cycle ownership update indicates JP Morgan's aggregated exposure across cash and derivatives, with 1.32% in indirect real holdings and 1.87% in indirect potential holdings, including equity swaps and convertible bonds. An AI analyst notes that while this is an ownership update, a larger threshold crossing or rapid changes in the real stake would be needed to be a bigger catalyst.
Advertisement

PTA-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG

https://www.tradingview.com/news/reuters.com,2026-10-30:newsml_Pexr7NGBa:0-pta-pvr-qiagen-n-v-release-according-to-article-40-section-1-of-the-wphg/
QIAGEN N.V. (QGEN) has released a voting rights announcement in accordance with Article 40, Section 1 of the WpHG, as informed by the AFM on October 29, 2026. The notification, related to a transaction on October 23, 2026, details that Massachusetts Financial Services Company holds 3.85% capital interest and 4.59% voting rights in QIAGEN N.V. The company explicitly states it is not responsible for the accuracy of the notification, which was taken from the AFM's public register.

QIAGEN N.V. (QIA) Reports AFM Voting Rights Notice

https://www.tradingview.com/news/tradingview:6138c263a5ff1:0-qiagen-n-v-qia-notes-afm-filing-on-barclays-voting-rights/
QIAGEN N.V. (QIA) has reported that the Dutch AFM (Authority for the Financial Markets) disclosed a voting rights notification concerning Barclays Plc, dated October 23, 2026. This regulatory ownership disclosure signals a change in a major holder’s position that could impact float and liquidity, though it is noted as a late confirmation rather than a new strategic shift. A more significant catalyst would be a subsequent filing indicating a specific percentage or threshold crossing.

QIAGEN N.V. (QIA): UBS Notifies 5.82% Voting Rights

https://www.tradingview.com/news/tradingview:dd8b6401ebcef:0-qiagen-n-v-qia-ubs-reports-5-82-voting-rights/
UBS Group AG has reported a 5.82% holding in QIAGEN N.V. (QIA) as of October 26, 2026, according to a disclosure by the Dutch AFM. This holding comprises 3.27% indirect real voting rights and 2.55% indirect potential voting rights through shares and derivatives. This ownership update reflects UBS's aggregate exposure and signals a notable stake in QIAGEN.

QIAGEN N.V. (QIA) Discloses AFM Notice on 2.6% Holding

https://www.tradingview.com/news/tradingview:6fbb053783475:0-qiagen-n-v-qia-reports-millennium-at-2-60/
QIAGEN N.V. (QIA) announced that the Dutch AFM reported Millennium International Management LP holds a 2.60% stake in the company as of October 23, 2026. This holding is primarily composed of potential voting rights from swaps and options, alongside a small direct ownership of 80,334 ordinary shares. An AI analyst notes that this disclosure signals tactical positioning rather than long-term ownership, with the derivatives amplifying potential exposure.

Earnings Preview: Qiagen NV to Report Financial Results Post-market on November 04

https://news.futunn.com/en/post/1002836231/earnings-preview-qiagen-nv-to-report-financial-results-post-market
Qiagen NV (NYSE:QGEN) is scheduled to announce its financial results post-market on November 4, having last reported earnings on August 3, 2026, where it beat EPS estimates but missed revenue expectations. Analysts anticipate an average revenue of $475.96 million and an EPS of $0.46 for the upcoming report. The company's stock has seen a 1-year low of $37.56 and a 1-year high of $50.77, currently trading near its 52-week high, with significant insider selling observed recently.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement